SCHEMBL26603232

SCHEMBL26603232

Cc1ccc(Cn2ncc3cccc(C(=O)O)c32)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FABP4 P15090 2/20 0.48
NPC1 O15118 2/20 0.46
LMNA P02545 1/20 0.46
ALDH1A1 P00352 4/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
HTT P42858 2/20 0.44
HSD17B10 Q99714 3/20 0.43
RECQL P46063 1/20 0.42
TP53 P04637 2/20 0.42
KDM4E B2RXH2 1/20 0.41
GAA P10253 1/20 0.41
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
RAB9A P51151 1/20 0.40
MEN1 O00255 1/20 0.40
MAPT P10636 1/20 0.40
HPGD P15428 1/20 0.40
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28448801 0.89 RECQL (0.54) FABP4ALDH1A1HTTHSD17B10RECQL
SCHEMBL12900334 0.88 TSHR (0.49) FABP4LMNAALDH1A1SMN1; SMN2HTT
SCHEMBL20541605 0.87 EGLN1 (0.49) FABP4ALDH1A1RECQL
SCHEMBL21506587 0.87 RECQL (0.42) FABP4ALDH1A1RECQLKMO
SCHEMBL26603233 0.86 LMNA (0.49) NPC1LMNAALDH1A1SMN1; SMN2HTT
SCHEMBL20541783 0.84 FABP4 (0.51) FABP4ALDH1A1SMN1; SMN2RECQLKDM4E
SCHEMBL30697456 0.84 FABP4 (0.51) FABP4ALDH1A1SMN1; SMN2RECQLKDM4E
SCHEMBL20542067 0.81 PPARD (0.44) ALDH1A1SMN1; SMN2RECQLTP53GAA
SCHEMBL30697464 0.81 PPARD (0.44) ALDH1A1SMN1; SMN2RECQLTP53GAA
SCHEMBL25966967 0.79 ALDH1A1 (0.49) FABP4NPC1LMNAALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11795156-B2 Bicyclic carboxamides and methods of use thereof TEMPEST THERAPEUTICS, INC. (US) 2023-10-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11795156-B2 Bicyclic carboxamides and methods of use thereof PTGER4, PTGER2, CNR2 FABP4 868/4885NPC1 3514/4885LMNA 1510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.